losortan potassium- losartan potassium tablet, film coated
zydus pharmaceuticals usa inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive
potassium phosphates- potassium phosphate, monobasic and potassium phosphate, dibasic injection, solution
fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp is indicated as a source of phosphate, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte of nutrient solutions. potassium phosphates is contraindicated in diseases where high potassium, high phosphate or low calcium levels may be encountered.
potassium citrate and citric acid- potassium citrate and citric acid monohydrate solution
pai holdings, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 1100 mg in 5 ml - potassium citrate and citric acid oral solution usp is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting and tolerable, even when administered for l
losortan potassium- losartan potassium tablet, film coated
remedyrepack inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 50 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive
losortan potassium- losartan potassium tablet, film coated
preferred pharmaceuticals inc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 50 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive
potassium chloride 15% (potassium 20mmol/10ml) solution for infusion 10ml ampoules
potassium 20mmol/10ml) solution for infusion 10ml ampoules (hameln pharma ltd - potassium chloride - solution for infusion - 150mg/1ml
potassium chloride 20% (potassium 13.3mmol/5ml) solution for infusion 5ml ampoules
potassium 13.3mmol/5ml) solution for infusion 5ml ampoules (hameln pharma ltd - potassium chloride - solution for infusion - 200mg/1ml
potassium chloride 15% (potassium 20mmol/10ml) solution for infusion 10ml ampoules
potassium 20mmol/10ml) solution for infusion 10ml ampoules (advanz pharma - potassium chloride - solution for infusion - 150mg/1ml
potassium chloride tablet, extended release
strides pharma science limited - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets, usp is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene and amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets, usp during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of
potassium chloride capsule, coated, extended release
golden state medical supply, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release capsules are indicated for the treatment and prophylaxis of hypokalemia in adults and children with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride extended-release capsules are contraindicated in patients on amiloride or triamterene. risk summary there are no human data related to use of potassium chloride extended-release capsules during pregnancy and animal reproductive studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti